Search Results

You are looking at 1 - 10 of 16 items for :

  • "tall cell" x
Clear All
Open access

Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh and Tetsuo Kondo

, undifferentiated and medullary carcinoma ( 2 ). Papillary thyroid carcinoma (PTC) is the most common subtype, which comprises more than 85% of thyroid cancers. Morphologically, PTCs are subdivided into variants, of which tall cell variant (TCV) is recognized as

Open access

June Young Choi, Jin Wook Yi, Jun Hyup Lee, Ra-Yeong Song, Hyeongwon Yu, Hyungju Kwon, Young Jun Chai, Su-jin Kim and Kyu Eun Lee

to clinicopathologic variables are shown in Table 1 . VDR gene expression was higher with statistical significance in classic and tall-cell variant PTC (TCVPTC) than that in follicular variant PTC (FVPTC). VDR expression was also significantly

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

follicular variant followed by the classical variant. Many rare variants such as columnar, clear cell, tall cell and diffuse sclerosing variant were identified. More than half PTCs were multifocal (46/83) and nearly half had extrathyroidal extension (37

Open access

Simonetta Piana, Eleonora Zanetti, Alessandra Bisagni, Alessia Ciarrocchi, Davide Giordano, Federica Torricelli, Teresa Rossi and Moira Ragazzi

regardless of the sub-histotype (classic, tall cell, follicular) as the staining was stronger in the cell surface toward the lumen of the follicles or the papillae ( Fig. 3 ). Luminal localization of NOTCH1 was largely associated to PTCs, while in the other

Open access

Joana Simões-Pereira, Daniel Macedo and Maria João Bugalho

variant 1 (3.7%)  Classical + follicular variants 1 (3.7%)  Classical + columnar variants 1 (3.7%)  Tall-cell variant 1 (3.7%)  Follicular + solid + cribiform variants 1 (3.7%) • FTC 2 (7.4%) • HCC 2 (7

Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

subgroup ( Table 1 ). Lung was the most frequent metastatic site (54.1%, data not shown). Of 151 cases, 88 were diagnosed as ‘classic-PTC’ (C-PTC, 58.3%), 25 as ‘Tall-cell Variant-PTC’ (TCV-PTC, 16.6%), 17 as ‘Follicular Variant-PTC’ (FV-PTC, 11.3%), 3 as

Open access

Erika Urbano Lima, Ileana G S Rubio, Joaquim Custodio Da Silva, Ana Luiza Galrão, Danielle Pêssoa, Taise Cerqueira Oliveira, Fabiane Carrijo, Igor Silva Campos, Luciano Fonseca Espinheira, Luiz Jose Sampaio, Claudio Rogerio Lima, Janete Maria Cerutti and Helton Estrela Ramos

the paired samples (T: 12.02 ± 1.1; NT: 12.14 ± 4.7). Differences in HOPX expression were observed between the subtype of PTC, tall cells showed higher expression (12.49 ± 0.7) than follicular variant (11.98 ± 0.8) ( P  = 0.006). The presence of BRAF

Open access

Katerina Saltiki, Elli Anagnostou, George Simeakis, Sofia Kouki, Anastasia Angelopoulou, Leda Sarika, Alexandra Papathoma and Maria Alevizaki

tumors were in their majority micro-PTC (7/9), while 3/9 were multifocal. The mean age at diagnosis of these patients was 45.2 ± 13.4 years (median 45 years). The majority had typical PTC features, while 1/9 was classified as tall cell variant. Lymph node

Open access

Natalie Su-Jing Yap, Richard Maher and Diana Louise Learoyd

/26  Tall cell variant 2/24 0/26  Hürthle cell variant 1/24 0/26  Mixed type 3/24 0/26  Hürthle cell carcinoma 1/24 0/26 AJCC/UICC TNM staging at diagnosis  I 12/24 14/26  II 1/24 2/26  III 2/24 6/26  IVa 7/24 2/26  IVb 1/24 0/26  IVc 0/24 1/26  Not

Open access

Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim and Erik K Alexander

scan showed intense FDG avidity in the sternal mass and mild avidity in a left lung nodule. She underwent resection of the mediastinal mass, confirming PTC with tall cell features. The patient was treated with radioactive iodine therapy (203 mCi dose